Recent Updates
Recently added Catalysts

TC-3 mixed with Botox

Phase 1

Interstitial Cystitis | Unknown | Urology |UroGen Pharma Ltd.|Last Updated: Apr 12, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment15

FDA Designations

No designations recorded

Clinical trial landscape

TC-3 mixed with Botox · 1 trial · 2 indications

Phase 1 1
NCT01997983Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC PatientsInterstitial Cystitis
COMPLETED15 Analytics
PHASE1COMPLETED
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
Interstitial CystitisUnlock trial analytics

Study Endpoints

Primary Endpoints

VAS score
week 12

Change from baseline in Visual Analog Scale (VAS) score for bladder pain measured at week 12 post BTX+TC-3 instillation.

Secondary Endpoints

Number of voids in 24hour period
12 weeks post instillation
NUmber of urge episodes in 24-hour period
12 weeks post instillation
number of nocturnal voids in one night
12 weeks post instillation
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TC-3 Gel with BotoxEXPERIMENTALopen label observational study

Interventions

NameTypeDescription
TC-3 Gel mixed with Botox (BTX)DEVICETC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Subject diagnosed with Interstitial Cystitis/PBS. 2. Subject has signed Informed Consent Form and is willing and able to abide by the protocol. 3. Subject has IC Symptom index (of IC Symptom and Problem Questionnaire) score of 12-20 points. 4. Subject has IC Problem index (of...

Countries:Israel
Unlock Eligibility Criteria

Frequently asked questions about TC-3 mixed with Botox

What is TC-3 mixed with Botox used for?

TC-3 mixed with Botox is an investigational intravesical gel being studied for the treatment of interstitial cystitis, a chronic bladder condition. It is administered as an instillation directly into the bladder. The combination is designed to deliver botulinum toxin within a gel formulation for local therapeutic effect.

Who makes TC-3 mixed with Botox?

TC-3 mixed with Botox is being developed by UroGen Pharma Ltd., a biopharmaceutical company focused on urological treatments. UroGen Pharma Ltd. trades on the NASDAQ under the ticker symbol URGN.

What phase is TC-3 mixed with Botox in?

TC-3 mixed with Botox is in Phase 1 clinical development. It has completed a Phase 1 trial, and the drug remains investigational, meaning it has not been approved by regulatory authorities. Further clinical studies would be required to assess its safety and efficacy.

What clinical trials is TC-3 mixed with Botox in?

TC-3 mixed with Botox has one completed clinical trial, registered as NCT01997983, titled "Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients." This Phase 1 study enrolled 15 participants with interstitial cystitis in Israel.

How does TC-3 mixed with Botox work?

TC-3 mixed with Botox combines botulinum toxin with a gel formulation for intravesical instillation. The botulinum toxin is intended to act locally within the bladder, potentially reducing pain and urinary symptoms associated with interstitial cystitis. The gel is designed to facilitate delivery and retention of the toxin in the bladder.

Is TC-3 mixed with Botox the same as Botox?

TC-3 mixed with Botox is not the same as Botox alone. It is a combination product that mixes botulinum toxin with a proprietary gel called TC-3, designed for intravesical delivery. This formulation is being studied specifically for interstitial cystitis, whereas Botox alone is used for various other indications.